Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center

The panelists conclude their discussion by highlighting investigational agents to look forward to.

Rami Komrokji, MD, presents to the panel a second clinical scenario of a 74-year-old with cytopenic myelofibrosis.

A look at the potential treatment options for a patient with myelofibrosis who progresses after first-line therapy.

Key opinion leaders discuss how they would approach treating a 67-year-old with myelofibrosis, presenting with splenomegaly.

Drs Palmer and Mesa explain the challenges of treating accelerated phase myeloproliferative neoplasms.

The panel reviews other exciting novel agents under investigation for myelofibrosis treatment.

Ruben Mesa, MD, discusses updates on the novel agent momelotinib from an abstract he presented at ASCO 2022.

Jamile Shammo, MD, FACP, explains the efficacy and safety of the 3 approved therapies for myelofibrosis.

Experts discuss data on the recently approved agents fedratinib and pacritinib for myelofibrosis treatment.

A review of data on the use of the JAK inhibitor ruxolitinib for patients with myelofibrosis.

The panel has a conversation on risk stratification for myelofibrosis and how it individualizes their treatment approaches.

Dr Jamile Shammo explains the process of diagnosing myelofibrosis and highlights the importance of bone marrow biopsies.

A discussion on assessing symptom burden and quality of life for patients with essential thrombocythemia or polycythemia vera.

Ruben Mesa, MD, details an abstract presented at ASCO 2022 on an investigational agent filling an unmet need in polycythemia vera.

An overview of the treatment options for patients with polycythemia vera.

Jamile Shammo, MD, FACP, FASCP, defines polycythemia vera and explains the process for diagnosis and risk stratification.

Dr Ruben Mesa describes how he treats patients with essential thrombocythemia and the available treatment options.

Jeanne Palmer, MD, explains essential thrombocythemia and how it’s diagnosed.

A thought leader in hematologic malignancies provides key insights into the future of treatment for polycythemia vera by considering the potential role of treatment sequencing or combination therapy.

Jamile Shammo, MD, FASCP, FACP, continues her discussion of ruxolitinib for polycythemia vera by examining the results of the RESPONSE-2 trial and sharing personal experience managing toxicity in clinic.

Renowned expert in the management of MPNs, Jamile Shammo, MD, FASCP, FACP, reviews the RESPONSE trial of ruxolitinib in patients with PV and discusses the agent’s safety and efficacy.

A specialist in hematologic malignancies provides an overview of the JAK2 pathway as it relates to myeloproliferative neoplasms such as polycythemia vera.

Jamile Shammo, MD, FASCP, FACP, shares insight into the currently available treatment options for polycythemia vera and examines how treatment intolerance and/or resistance can impact the therapeutic approach.

A key opinion leader in the management of polycythemia vera discusses risk stratification and reflects on factors that influence the decision to observe or treat the patient’s disease.

An expert in hematologic malignancies, Jamile Shammo, MD, FASCP, FACP, provides an overview of the 2016 WHO diagnostic criteria for polycythemia vera and considers the role of genetic testing.

Expert panelists review important disease-related and patient-related factors when considering bone marrow transplant in patients with primary myelofibrosis.

Pankit Vachhani, MD, guides a discussion on the FDA approval of fedratinib and reviews how it has affected the therapeutic landscape for patients with primary myelofibrosis.

MPN expert Srdan Verstovsek, MD, PhD, shares insights into the role of ruxolitinib for the treatment of myelofibrosis.

An expert in the management of myeloproliferative neoplasms, Jamile Shammo, MD, FASCP, FACP, leads a discussion on best practices for assessing response and monitoring for progression.

Pankit Vachhani, MD, reviews recent changes to the NCCN Guidelines, highlighting the addition of luspatercept for the treatment of primary myelofibrosis.